Amphastar Pharmaceuticals(US:AMPH)2021-06-25 21:06Company Overview - Amphastar is a biopharmaceutical company focused on developing and manufacturing technically challenging BLAs, NDAs, and ANDAs in injectable, inhalable, and intranasal formulations[38] - The company has a strong base business with approximately $350 million in 2020 revenue and approximately $143 million in 2020 gross profit[38] - Amphastar has a robust pipeline of over 20 product candidates, including insulin products, in markets with barriers to entry[38] - The company has vertically integrated infrastructure and technical expertise for products with high barriers to market entry[38] Financial Performance - In 2020, Primatene MIST® contributed $52 million to net revenue[16] - Enoxaparin contributed $49 million to net revenue in 2020[16] - Vitamin K1 contributed $43 million to net revenue in 2020[16] - Lidocaine contributed $41 million to net revenue in 2020[16] - Naloxone contributed $33 million to net revenue in 2020[16] - Epinephrine contributed $24 million to net revenue in 2020[16] - Insulin API contributed $18 million to net revenue in 2020[16] - Other Pharma Products contributed $90 million to net revenue in 2020[16] - The company's self-funded R&D investment was approximately $280 million in the recent 5 years[17] Pipeline and R&D - The company has 12 generic pipeline candidates with technical barriers, including products with IQVIA sales of +$300 million, +$50 million, +$580 million, +$750 million, +$500 million, and +$2.5 billion[25] - The company is developing three insulin and protein candidates, targeting a US market with IQVIA sales of ~$13 billion[26] - Sales of Eli Lilly's Glucagon Emergency Kit were approximately $144 million[30]